TechNet-21 - Forum

Ce forum est un lieu d'échange où les membres peuvent poser des questions, partager leurs expériences, coordonner des activités, et discuter les récentes avancées en matière de vaccination.
  1. craig burgess
  2. Gestion du programme
  3. lundi 2 mai 2016

Dose per Container Partnership (DPCP)


The issue: Multi-dose containers are used to offer lower prices, higher supply volumes, and minimize cold chain storage and distribution requirements. As new, more expensive, vaccines are introduced in multi-dose presentations, maximizing the use of every dose in a container increases in importance. HCWs need to be more strategic about when to open a container; diligent about how they care for open containers, and potentially more active with communication and community outreach to ensure optimal attendance and timely vaccination of every child. Thus, the number of doses per container (DCP) may also impact on health systems in terms of timely, safe and equitable vaccination coverage, supply and cold chain, wastage rates, cost and HCW behavior.


Immunization stakeholders need information and tools to assess which dose per container presentations are appropriate for a country’s specific context and priorities.


Initial 2015 response: With Bill & Melinda Gates Foundation (BMGF) funding, JSI Research & Training Institute, Inc. (JSI) helped identify evidence gaps by interviewing key stakeholders and analyzing existing research. An informal network of partners interested in advancing this work was created after a consultative meeting in July 2015.


Launch of the partnership: The Dose Per Container Partnership (DPCP) was launched in March 2016 as a project, funded by the BMGF and implemented by JSI in partnership with PATH, Agence de Médecine Préventive (AMP), Clinton Health Access Initiative (CHAI), HERMES modeling team and the International Vaccine Access Center (IVAC) / Johns Hopkins University. The DPCP aims to address the complexity of vaccine product and program decision-making to include DPC considerations. Understanding and assessing the trade-offs between cost and health impact allows better informed decisions about the impact of the dose per container selected.


DPCP objectives and work streams: The DPCP project will run from February 2016 – December 2017, guided by a Technical Advisory Group (TAG), and aims to achieve two objectives:


i) To gain a deeper understanding of the decision making processes, trade-offs, data


and tools used to assess DPC decisions at global and national levels in order to recommend process improvements;


ii) To provide guidance and tools including trade-offs to be considered by countries and facilitate


sharing of best practices for country level decision makers.


These will be implemented through three technical work streams:



  1. A global cross-country review of current DPC-related decision making tools and processes;

  2. Prospective research studies in two African countriesl will include data collection to improve modeling efforts, economic analysis and see the actual effect on the various systems variables; and

  3. Synthesis of data supporting global level policy and country decisions.



Stakeholders: DPCP aims to inform, support and influence stakeholders at:


a) Global level, by providing evidence that fills critical gaps in knowledge, analysis, and policy. This includes ensuring that stakeholders will continue to be informed about sustainable decisions on DPC when considering vaccine products and program designs; and


b) Country level, by producing easy-to-use and -understand guides and tools to assess DPC tradeoffs, including cost and systems impact to inform vaccine product selection


Information about the DPCP will be made available through partners engaged with the project, the JSI website, announcements via the technet forum and various formal and informal opportunities where immunization practitioners meet globally, regionally or nationally.


http://jsi.com/JSIInternet/IntlHealth/project/display.cfm?ctid=na&cid=na&tid=40&id=22641

Dr Daudi Manyanga Réponse acceptée

Thanks Craig for raising a very interesting area of interest, DPCP a challenge in decision making especially in low income countries. For readers information, for vaccines like BCG where one vial has 20 doses and some one vaccinate only 2 children. The vaccine wastage is approximately 90%, in this regard 90% of funds used for procurement, storage and transportation in other words is thrown away! Its time to re-think the focus of our investiment

  1. il y a plus d'un mois
  2. Gestion du programme
  3. # 1
Bhupendra Tripathi Réponse acceptée

Hi Craig,

Am sharing an innovative approach developed by Fluid Management System (FMS) team to track the remaining vaccine dose in a partially used mult-dose vial.

What is Smartray™? - Vaccine Wastage Assessment & Tracking Internet of Things IoT System

  • Non-Invasive Measurement of Fluid Levels Inside Sealed Vials and transmit that data or information wirelessly to central tacking and monitoring system.
  • Addressed and solved vaccine waste in multi-dose vials and vaccine measurement & tracking from manufacturer to supply-chain to vaccine administered or given site.
  • Customizable Product to Industry needs and Requirements
  • Smartray™ System (Hardware & Software) - For Vaccine or Liquid Open Vial Wastage Reduction Tracking, Operating Cost $ and Environment Saving
  • Internet of Things(IoT)- Smartray™ Sensor, Electronics, Software & Network Connectivity Enables to Measure vaccine liquid level, Collect and Exchange Liquid Data.

The Smartray™ the heart of the system is a low cost, fast yet highly accurate method for determining liquid level inside small sealed vial, such as multi-dose vaccine vials(1ml to 10ml).

The non-invasive technique easily determines the number of doses remaining in the vaccine vial. The motivation for such precise measurement is to control and monitor vaccine usage, reduce waste and automate the inventory process.

The link to the site ishttp://fluidmanagementsystem.com/and the contact person is Mr. Ajay Das.

Being an innovative technique, it needs proper guidance from the Technical Experts to see the feasibility and adaptability of this solution in immunization program in the countries. Can the DPCP analyze the potential of this solution for future.

Best Regards,

Bhupendra

  1. il y a plus d'un mois
  2. Gestion du programme
  3. # 2


Cette discussion ne contient encore aucune réponse.
Soyez le premier à y répondre !